TIDMAKR

RNS Number : 5058K

Akers Biosciences, Inc.

31 December 2015

Akers Biosciences, Inc.

Issue of Equity & Directors' Shareholdings

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that, pursuant to the Company's 2013 Incentive Stock and Award Plan, as amended, the Company has allocated for issuance an aggregate of 280,208 shares of the Company's restricted common stock, of no par value per share ("Restricted Stock") for nil consideration. The Restricted Stock is to be issued to certain officers and directors (the "Grantees") for services rendered to the Company.

As a result of the allocation of Restricted Stock, the Company sets out below the changes in the directors' interests in the Company:

 
 Director                   Number of        Number of      Number           Percentage 
                        Common Shares      shares held    of Stock             of total 
                           held prior        after the     Options          outstanding 
                    to the allocation       allocation        held    shares (excluding 
                        of Restricted    of Restricted                      unexercised 
                                Stock            Stock                   Stock Options) 
 Thomas J. 
  Knox                        408,150          478,150      20,000               8.81 % 
 Brandon 
  Knox                         83,076          138,076      20,000               2.55 % 
 Robert Andrews                     -           48,125           -               0.89 % 
 Raza Bokhari                       -           32,083           -               0.59 %

Application has been made for the 280,208 Restricted Stock shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place on 7 January 2016.

The new Restricted Stock will rank pari passu with the existing shares of the Company. Subsequent to Admission, the total number of issued ordinary shares will be 5,425,045. There are no ordinary shares held in treasury and so the total number of voting rights in the Company will be 5,425,045.

The above figures may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Akers Biosciences, Inc.

Raymond F. Akers, Jr. PhD

Executive Chairman of the Board

Tel. +1 856 848 8698

Taglich Brothers, Inc. (Investor Relations)

Chris Schreiber

Tel. +1 917 445 6207

Email: cs@taglichbrothers.com

finnCap (UK Nominated Adviser and Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel. +44 (0)20 7220 0500

Vigo Communications (Public Relations)

Ben Simons / Fiona Henson

Tel. +44 (0)20 7016 9570

Email: akers@vigocomms.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEANAEDDLSFFF

(END) Dow Jones Newswires

December 31, 2015 02:00 ET (07:00 GMT)

Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Akers Biosciences Charts.
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Akers Biosciences Charts.